SoC Chemotherapy

DRUG3 trials

Sponsors

Ludwig-Maximilians - University of Munich, Kathy Miller, West German Study Group

Conditions

Breast CancerEstrogen-receptor-low Breast CancerMetastatic Breast CancerPancreatic CancerTriple Negative Breast CancerTriple-negative Breast Cancer

Phase 2

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

TerminatedNCT05114213

Ludwig-Maximilians - University of MunichPancreatic Cancer

Start: 2021-12-15End: 2025-11-11Updated: 2025-12-05

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

RecruitingNCT05846789

Kathy MillerEstrogen-receptor-low Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer

Start: 2024-07-02End: 2026-12-01Target: 168Updated: 2026-01-21

Phase 3

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not yet recruitingNCT07178730

West German Study GroupBreast Cancer, Triple-negative Breast Cancer

Start: 2026-01-31End: 2033-03-31Target: 765Updated: 2025-09-17

Related Papers

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)

Radiation Oncology2022-01-2518 citations